Key Points
Error: Response status code does not indicate success: 530 ().
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $30.68, for a total value of $460,200.00. Following the completion of the transaction, the chief executive officer directly owned 671,907 shares in the company, valued at approximately $20,614,106.76. The trade was a 2.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Cameron Turtle also recently made the following trade(s):
- On Monday, December 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $29.02, for a total value of $435,300.00.
- On Monday, November 3rd, Cameron Turtle sold 45,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $23.33, for a total transaction of $1,049,850.00.
Spyre Therapeutics Trading Up 1.2%
Shares of NASDAQ:SYRE opened at $30.33 on Wednesday. The firm has a market cap of $2.35 billion, a PE ratio of -13.85 and a beta of 3.17. The company has a fifty day simple moving average of $28.99 and a 200 day simple moving average of $21.32. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $35.31.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.53. As a group, equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. BTIG Research reissued a "buy" rating and issued a $70.00 price objective on shares of Spyre Therapeutics in a report on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft started coverage on Spyre Therapeutics in a research report on Friday, September 26th. They issued a "buy" rating and a $43.00 target price for the company. Citigroup initiated coverage on Spyre Therapeutics in a research report on Wednesday, December 17th. They set a "buy" rating and a $64.00 price target on the stock. Wall Street Zen raised shares of Spyre Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, November 16th. Finally, Mizuho upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $53.88.
Read Our Latest Stock Analysis on SYRE
Institutional Trading of Spyre Therapeutics
Several hedge funds have recently made changes to their positions in SYRE. TCG Crossover Management LLC bought a new position in Spyre Therapeutics during the 3rd quarter worth $18,446,000. Millennium Management LLC acquired a new position in shares of Spyre Therapeutics during the third quarter valued at $6,841,000. Baker BROS. Advisors LP grew its position in shares of Spyre Therapeutics by 59.6% during the third quarter. Baker BROS. Advisors LP now owns 1,000,000 shares of the company's stock worth $16,760,000 after acquiring an additional 373,297 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Spyre Therapeutics by 483.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 275,984 shares of the company's stock worth $4,625,000 after acquiring an additional 228,705 shares during the period. Finally, Parkman Healthcare Partners LLC bought a new stake in Spyre Therapeutics in the 3rd quarter valued at about $3,365,000. Institutional investors own 80.39% of the company's stock.
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
